New Hepatocyte Model Systems to study Hepatitis B Virus Infection
New Hepatocyte Model Systems to study Hepatitis B Virus Infection
批准号:
8679475
负责人:
Robert E Schwartz
金额:
$15.35万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-15 至 2019-02-28
关键词:
AdultAgingAmericanB-LymphocytesBiological ModelsBiologyCell LineCellsCellular TropismChemicalsChronic Hepatitis BCirrhosisClinicalGeneticHepatitis BHepatitis B VirusHepatocyteHumanImmunosuppressionInfectionLife Cycle StagesMetabolicModelingPathway interactionsPatientsPhenotypePlayPluripotent Stem CellsPrimary carcinoma of the liver cellsProcessProductionRegulationRiskRoleStem cellsSystemTechniquesUnited StatesVaccinesVariantViralViral PathogenesisViral ProteinsViral hepatitisVirionVirusVirus DiseasesVirus ReplicationWorkgenetic varianthepatoma cellhuman stem cellsin vitro Modelinduced pluripotent stem cellinnovationinsightpermissivenesspreventpublic health relevanceresponsescreeningtherapeutic developmenttoolviral DNAvirus pathogenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Worldwide, hepatitis B virus (HBV) infection is the most common viral hepatitis having infected
over two billion people and chronically infecting more than 400 million, putting them at increased
risk to develop cirrhosis and hepatocellular carcinoma. In the United States over one million
people have chronic hepatitis B infection. Clinical therapy is targeted to the suppression of viral
replication but the virus is able to persist in a nonreplicative covalently closed circular form
called cccDNA, with the potential to reactivate upon immune suppression or with aging. As a
consequence, the hepatitis B virus in chronic HBV infections is challenging to eradicate and
cure is rare. The difficulty in developing new HBV therapies has been due to the lack of good
model systems. The current model system to study hepatitis B has been hepatoma cell lines in
which HBV is over expressed transiently or stably to produce all viral gene products and
maintain replication. However such models over express HBV in a non-physiological manner
and do not faithfully recapitulate adult hepatocyte phenotype or function as they have
undergone a variety of genetic and metabolic changes. As a consequence, the viral entry
factors as well as the regulatory processes of viral replication have been poorly understood.
This has prevented development of therapeutic strategies that achieve viral control and
eradication. This proposal builds on new tools and techniques that enable the long-term culture
of metabolically functional primary human hepatocytes and the establishment of pluripotent
stem cell derived hepatocyte-like cells. Both innovations enables the exploration of the
determinants of HBV entry, viral replication, and the cccDNA state which will open new
opportunities to better understand HBV biology and develop new targeted therapies. The
establishment of a culture model system that is permissive for HBV infection and also enables
the long-term culture of metabolically functional primary human hepatocytes represents a new
opportunity to explore the determinants of HBV entry, viral replication, and cccDNA formation
and persistence (Aims 1-2). In contrast to current hepatoma cell lines, a functional hepatocyte
screening platform will enable the study of the role that biologic pathways play in the HBV viral
life cycle's choice towards cccDNA production versus active HBV virion production (Aim 2).
These pathways can then be explored and dissected in detail in induced pluripotent derived
stem cell derived variants to determine their impact on hepatocyte permissiveness, hepatitis B
virus pathogenesis and cccDNA formation (Aim 3). Better insights in HBV pathogenesis,
cccDNA formation, virus evasion and the determinants of hepatocyte autonomous responses
may also be translational as treatment options for chronically infected HBV patients are
available but are unable to eliminate cccDNA leading to lifelong infection and requirements for
lifelong treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of the engineered 3D hepatic microenvironment enhances pluripotent stem cell derived hepatocyte
-
批准号:10089438
-
项目类别:
-
资助金额:$75.81万
-
财政年份:2020
-
负责人:Robert E Schwartz
-
依托单位:
Optimization of the engineered 3D hepatic microenvironment enhances pluripotent stem cell derived hepatocyte
-
批准号:10352208
-
项目类别:
-
资助金额:$38.14万
-
财政年份:2020
-
负责人:Robert E Schwartz
-
依托单位:
Optimization of the engineered 3D hepatic microenvironment enhances pluripotent stem cell derived hepatocyte
-
批准号:9887203
-
项目类别:
-
资助金额:$38.14万
-
财政年份:2020
-
负责人:Robert E Schwartz
-
依托单位:
Optimization of the engineered 3D hepatic microenvironment enhances pluripotent stem cell derived hepatocyte
-
批准号:10221299
-
项目类别:
-
资助金额:$38.14万
-
财政年份:2020
-
负责人:Robert E Schwartz
-
依托单位:
Optimization of the engineered 3D hepatic microenvironment enhances pluripotent stem cell derived hepatocyte
-
批准号:10579860
-
项目类别:
-
资助金额:$38.14万
-
财政年份:2020
-
负责人:Robert E Schwartz
-
依托单位:
Modeling Hepatoblastoma using pluripotent stem cell derived hepatocyte-like cells
-
批准号:10222621
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2019
-
负责人:Robert E Schwartz
-
依托单位:
Modeling Hepatoblastoma using pluripotent stem cell derived hepatocyte-like cells
-
批准号:10687102
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2019
-
负责人:Robert E Schwartz
-
依托单位:
New Hepatocyte Model Systems to study Hepatitis B Virus Infection
-
批准号:8808760
-
项目类别:
-
资助金额:$15.35万
-
财政年份:2014
-
负责人:Robert E Schwartz
-
依托单位:
New Hepatocyte Model Systems to study Hepatitis B Virus Infection
-
批准号:9016547
-
项目类别:
-
资助金额:$15.35万
-
财政年份:2014
-
负责人:Robert E Schwartz
-
依托单位:
海外基金